Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 17, Number 2—February 2011

Dispatch

Novel HIV-1 Recombinant Forms in Antenatal Cohort, Montreal, Quebec, Canada

Mathieu Quesnel-Vallières, Iman Kouzayha, Evelyne Tran, Issatou Barry, Charlène Lasgi, Natacha Merindol, Vanessa Monteil, Doris G. Ransy, Marc Boucher, Normand Lapointe, and Hugo SoudeynsComments to Author 
Author affiliations: Author affiliations: Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada (M. Quesnel-Vallières, I. Kouzayha, E. Tran, I. Barry, C. Lasgi, N. Merindol, V. Monteil, D.G. Ransy, M. Boucher, N. Lapointe, H. Soudeyns); Université de Montréal, Montreal (M. Quesnel-Vallières, I. Kouzayha, E. Tran, I. Barry, N. Merindol, D.G. Ransy, M. Boucher, N. Lapointe, H. Soudeyns); Université Pierre et Marie Curie, Paris, France (C. Lasgi)

Main Article

Table

Virologic and immunologic parameters in patients participating in antenatal cohort, Canada*

Patient Age, y CD4 count, cells/mm3 Viral load, RNA copies/mL Antiretroviral treatment
TV721 33.2 210 164 AZT-3TC-NVP
TV725 30.1 816 739 None
TV749 34.1 198 23,369 AZT-3TC-NFV
TV919 34.0 420 1,910 AZT-3TC-NFV

*AZT, zidovudine; 3TC, lamivudine; NVP, nevirapine; NFV, nelfinavir.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO